Forget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You Need

Regencell Bioscience (NASDAQ: RGC), a China-based drugmaker, has been on fire over the past 12 months, with its share price skyrocketing by more than 21,000% as of this writing (that's not a typo). A closer look at the company, however, makes it hard to understand its performance over the past year and its valuation.Regencell looks like a rather speculative bet, and investors should look elsewhere, for instance, toward a well-established drugmaker like Pfizer (NYSE: PFE). Here's why this blue chip healthcare giant is a better bet.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool